Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Incyte, a drug discovery and development company focused on developing proprietary small molecule drugs, has appointed Patricia Andrews as its new executive vice president and chief commercial officer, effective October 20, 2008.
Subscribe to our email newsletter
Ms Andrews was most recently vice president and general manager of the US Oncology business unit. Ms Andrews has an MBA from the University of Michigan and a BA from Brown University.
Incyte has also announced the resignation of John Keller, Incyte’s executive vice president and chief business officer. Dr Keller is leaving Incyte to join a major pharmaceutical company.
Paul Friedman, president and CEO of Incyte, said: “We are very fortunate to have Pat join our management team. Her strong sales and marketing background, as well as her business development and strategic planning experience, will be invaluable as we continue to advance our pipeline and prepare for the potential commercialization of our first product.”